What Parents and Caregivers of a Child With IgA Nephropathy Should Know When Every Approved Drug Is Labeled for Adults

None of the 7 medicines the FDA has approved for IgA nephropathy is approved for that disease in children. IgA nephropathy, often shortened to IgAN, is a kidney disease in which an antibody called IgA collects in the kidney's tiny filters and inflames them. Every one of those 7 labels covers adults, and each says that safety and effectiveness in children have not been established. A parent or caregiver of a newly diagnosed child or teenager is working with 2 things at once. One is a care plan built without a pediatric drug label, and the other is a short list of company studies for children.

Children also tend to reach the diagnosis by a different road than adults do. The International Pediatric Nephrology Association (IPNA) published recommendations for children with IgAN in Pediatric Nephrology's 2025 volume. Its authors write that a child usually comes to attention with visible blood in the urine during an infection such as a cold. This guide starts with that first sign and moves through what the IPNA recommends, which drugs are being tested in children, and what to ask at the next visit.

Blood in the Urine During a Cold, the Usual First Sign of IgA Nephropathy in Children

In children, IgA nephropathy most often shows itself as red or brown urine while the child is sick with a sore throat, cold or other upper respiratory infection. Doctors call this synpharyngitic hematuria, which means blood in the urine that arrives alongside the infection rather than after it (IPNA, 2025). In a US series of 218 children from the Southwest Pediatric Nephrology group, 79% had visible blood in the urine when they were diagnosed, according to the IPNA's review. When the disease shows up in childhood, the median age at presentation is 10.9 years, in a reported range from 2.5 to 19.6.

Timing is the detail a parent or caregiver can report that helps a doctor most. Blood that shows up 1 to 3 weeks after a sore throat points toward a different condition, post-infectious glomerulonephritis. That one usually comes with a low blood level of a protein called C3. The IPNA suggests considering IgAN when visible blood lasts longer than 2 to 3 weeks during an infection, or keeps coming back with infection after infection.

Only a kidney biopsy can confirm the diagnosis, and the IPNA states that as a firm requirement. The urine protein-to-creatinine ratio (UPCR) is a spot-urine measure of leaked protein. The IPNA recommends a biopsy when blood in the urine persists or returns and the UPCR stays above 0.5g/g on 2 tests 1 to 2 weeks apart. A biopsy should happen promptly when protein reaches the nephrotic range or kidney function is reduced, the recommendations add.

Those urine tests are ideally done on the first urine of the morning. Some healthy children leak protein only while standing up, a harmless pattern called orthostatic proteinuria, and an early-morning sample rules it out. The IPNA's list of look-alikes also includes Alport syndrome, an inherited condition that causes blood in the urine and sometimes hearing loss. A family history of blood in the urine and kidney disease is one reason the guideline gives for considering genetic testing.

“Compared to adults, pediatric IgA nephropathy has a more acute presentation”

IPNA clinical practice recommendations, Pediatric Nephrology, 2025

Adults are mostly diagnosed after a routine urine test or because protein turns up in their urine, according to a large Chinese study the IPNA cites. Children more often arrive with visible blood during an infection, which leads to an earlier biopsy. A child's biopsy tends to show more active inflammation and less of the scarring that marks long-standing damage, the recommendations say. That kind of scarring is strongly tied to later kidney failure.

That difference is also why adult results do not carry over neatly. The IPNA authors write that evidence in children is thin partly because adult study data are hard to apply to a disease that behaves differently in a child. Repeated bouts of visible blood look alarming, yet the IPNA cites evidence that they go with a better outlook than a single episode or no visible blood at all.

The long view varies widely from one child to the next. In a Japanese study of 241 children cited by the IPNA, 5% had chronic kidney disease 5 years after onset, 6% by 10 years and 11% by 15 years. Among 96 untreated children with mild biopsy findings, 59.4% saw their urine abnormalities clear on their own within an average of 5.9 years. About 1 in 6 of those, 17.5%, later saw the abnormalities return.

Those relapses are why the IPNA recommends long-term follow-up even after a child's urine clears, plus a blood pressure check and urine test every year for life. The risk factors it lists for a worsening course include protein that stays high, ongoing blood in the urine, high blood pressure and reduced kidney function at biopsy.

IgA Nephropathy Approvals Since 2021, From None to 7

Every FDA approval for IgA nephropathy has come since December 2021, according to the drugs' labels and makers.

• December 2021: Tarpeyo (budesonide), with full approval in December 2023
• February 2023: Filspari (sparsentan), with full approval in September 2024
• August 2024: Fabhalta (iptacopan), with full approval on July 16, 2026
• April 2, 2025: Vanrafia (atrasentan)
• November 25, 2025: Voyxact (sibeprenlimab)
• July 2026: Trutakna (atacicept)
• October 21, 2026: Ultomiris (ravulizumab), announced by AstraZeneca

All 7 arrived in under 5 years, and 6 of them are now in studies that include children, the step that comes before a label can cover kids.

Which IgA Nephropathy Drugs Are FDA-Approved for Children?

No IgA nephropathy medicine is FDA-approved for children as of November 9, 2026. All 7 approved drugs are labeled for adults, and the pediatric-use section of each label says safety and effectiveness in children have not been established. The 7 are Tarpeyo (budesonide), Filspari (sparsentan), Fabhalta (iptacopan), Vanrafia (atrasentan), Voyxact (sibeprenlimab), Trutakna (atacicept) and Ultomiris (ravulizumab).

Two labels can confuse a family that reads them closely. Filspari's label covers children 8 and older with a different kidney disease, FSGS, yet states that its safety and effectiveness in children with IgAN have not been established. Ultomiris is approved from 1 month of age for 2 blood and kidney disorders, PNH and aHUS, while its IgAN dosing covers only adults who weigh 40kg or more.

Put side by side, the labels and the registry tell a family something neither says alone. As of November 9, 2026, all 7 FDA-approved IgA nephropathy drugs are labeled for adults only, and 6 of the 7 are in company studies registered to enroll children. Trial Friend found that by reading the pediatric-use section of each label and matching every drug against registry records for IgAN studies that accept patients under 18.

The next IgA nephropathy drug in line follows the same adult-only pattern. According to Vertex, its application for povetacicept covers adults with IgAN and has an FDA target date of November 30, 2026. Trial Friend will post the outcome on its povetacicept FDA calendar page.

What the 2025 IPNA Recommendations Say About Caring for a Child With IgA Nephropathy

The authors explain that KDIGO's main adult guideline was created without broad input from pediatric nephrologists, which is why the IPNA wrote its own. A voting panel of pediatric nephrologists drawn from every IPNA regional society had to reach more than 70% agreement on each statement. The authors are candid that much of it rests on little high-quality evidence in children, and they grade each statement by the strength of that evidence.

Treatment decisions in the recommendations rest mainly on the amount of protein in the urine, blood pressure and kidney function, and they fall into 4 broad steps.

• For a child with no sign of risk, such as blood visible only under a microscope or a bout of visible blood that cleared completely, the IPNA recommends no specific treatment and regular re-checks.
• When the UPCR stays at 0.2g/g or more, it recommends keeping salt under 3 to 5g a day and an ACE inhibitor or ARB, blood pressure medicines that also reduce protein leak, at the highest dose the child tolerates.
• If the UPCR is still 1.0g/g or higher after 3 to 6 months on that medicine, the authors write that a change toward immunosuppressive treatment should be considered.
• It does not recommend routine steroids, removing the tonsils as a treatment, or fish oil, though steroids can be considered in selected cases.

One line in the ACE inhibitor section matters for teenage girls. The IPNA notes that these medicines are absolutely contraindicated in anyone who is pregnant or may become pregnant, because they can harm a developing baby. Teens on one of them, and their families, can ask the nephrologist how that risk is handled as they get older.

Between visits, the IPNA's checklist calls for a first-morning UPCR and kidney function test every 3 months. It also lists blood pressure every 3 months and height and weight every 6 months. At each 3-month visit the history covers rashes, fatigue, fevers and school attendance. A simple log of sick days and missed school is worth bringing for that reason.

How the Newer IgA Nephropathy Medicines Work, in Plain Words

IgA nephropathy starts when the body makes a faulty form of an antibody called IgA. It builds up in the kidney's tiny filters, sets off inflammation and lets protein leak into the urine. The newer medicines act at different steps of that chain, according to their FDA labels.

• Easing the strain on the filters: ACE inhibitors and ARBs, the usual first medicines for children, lower the pressure inside the kidney's filters. Filspari (sparsentan) blocks 2 signals that tighten blood vessels, and Vanrafia (atrasentan) blocks 1 of them, which lowers how much protein leaks.
• Making less of the faulty IgA: Tarpeyo (budesonide) is a steroid released in the lower small intestine, where some of the faulty IgA is thought to be made. Voyxact (sibeprenlimab) and Trutakna (atacicept) block signals that immune cells need to make it.
• Calming part of the immune attack: Fabhalta (iptacopan) and Ultomiris (ravulizumab) block parts of the complement system, a branch of the immune system that adds to the damage. Complement also helps fight some bacteria, so both require certain vaccines before treatment starts.

A child's body can handle a medicine differently from an adult's, so each drug needs its own studies in children before its label can include them. The children's studies check safety and how much urine protein drops. Some, such as Novartis's Vanrafia study, also measure how much medicine reaches the blood at each weight, which is how a child's dose gets set.

Sibeprenlimab and the Other IgA Nephropathy Studies Enrolling Children

Company-sponsored studies are now registered to enroll children with IgAN for 6 of the 7 approved drugs, and Otsuka's sibeprenlimab study for ages 2 to 17 is the newest. The IPNA itself calls enrolling children in these trials a priority, as the newer drugs begin to be studied in them. Each study is open label, meaning every child gets the study drug and families know it.

Otsuka's Sibeprenlimab Study for Ages 2 to 17 (NCT07770815)

Otsuka's Phase 3 study plans to enroll about 24 children and teens ages 2 to 17. Each would get sibeprenlimab, the drug sold to adults as Voyxact, as a weight-based shot under the skin every 4 weeks for 48 weeks. The shots are added to the child's usual ACE inhibitor or ARB, and the main measure is the change in urine protein at week 40.

The listing asks for a biopsy-confirmed diagnosis and at least 12 weeks on a steady, maximally tolerated ACE inhibitor or ARB. A child's UPCR, the urine protein number, must average at least 0.75g/g across 3 first-morning samples. The eGFR, the kidney filtering number, must be 30 or higher. An IgG level of at least 600mg/dL is also required, a blood test of the immune system's main antibody, and no other kidney disease can be present.

As of November 9, 2026, ClinicalTrials.gov lists the study as Not yet recruiting with no sites, and Otsuka's own trial page shows it as Will Be Recruiting with no locations. The registry's estimated start date of October 30, 2026 has passed and the record still says Not yet recruiting, with primary completion estimated for December 29, 2029. Otsuka's study line is 844-687-3522, and Trial Friend's study page pre-checks the main requirements privately in your browser.

Ultomiris, Fabhalta, Vanrafia, Filspari and Trutakna Studies That Take Children

The other 5 company studies differ most in where they run and how heavy a child must be. Novartis's Fabhalta study lists 5 recruiting US sites, and its first group is teens 12 and older weighing at least 35kg, at the adult dose of 200mg twice a day. The dose for children under 12 has not been set yet, according to the listing. Novartis's Vanrafia study takes children down to 10kg, but its 4 US sites were all listed as not yet recruiting.

Alexion's I CAN junior study of Ultomiris requires meningococcal, Hib and pneumococcal vaccines before the first infusion, and the Fabhalta study requires meningococcal and pneumococcal vaccines too. Travere's EPPIK study of Filspari has run since 2021 and lists 17 recruiting US sites, the most of any study here. Vera's PIONEER study of Trutakna includes children, but every participant must weigh at least 40kg.

Several requirements repeat across the 6 studies, starting with a kidney biopsy confirming IgAN and an eGFR of 30 or higher. Most also want a steady stretch on an ACE inhibitor or ARB first, from 8 weeks to 120 days depending on the study. Most set the urine protein bar at a UPCR of 1.0g/g, while the sibeprenlimab study's 0.75g/g and one EPPIK group's 0.6g/g are lower. The Ultomiris and Novartis studies also want a biopsy from within the last 3 years, or a new one.

Older teens have one more option outside the approved drugs. Akebia's Phase 2 study of an experimental drug called ADX-097 accepts people 16 and older with IgAN and lists 3 recruiting US sites. Studies in China of telitacicept and of early-stage CAR-T cell treatments also list children with IgAN, but none has a US site.

Your Child Gets a Say in Joining a Study

In a children's study, a parent or guardian gives permission, and the child is usually asked to agree as well. That agreement is called assent, and an FDA rule requires the study's ethics board to plan for it whenever a child is able to give it.

The board weighs each child's age, maturity and emotional state when deciding who can assent and how that is recorded, under the same rule. Assent can be skipped only in narrow cases, such as a child too young to be asked, or a study offering an important direct benefit available nowhere else.

Families can ask the study team how assent works for a child their age, and how the study is explained to kids.

What a Children's Study Could Mean for a School Year

Each listing shows how often the study drug is given, which hints at how many visits a school year could hold. These counts come from the dosing schedules alone, so they are Trial Friend estimates, and real calendars usually add check-ups and blood tests.

• Voyxact (sibeprenlimab) study: a shot every 4 weeks for 48 weeks, about 12 shots in all
• Ultomiris (ravulizumab) study: an IV infusion every 4 or 8 weeks depending on weight, roughly 6 to 13 a year
• Trutakna (atacicept) study: a shot once a week
• Fabhalta, Vanrafia and Filspari studies: medicine by mouth at home, with clinic visits for checks

Ask the study team for the full visit calendar before deciding, and share it with the school when building a 504 plan or a health plan.

School, Sports and Everyday Life With IgA Nephropathy

Regular exercise is part of the IPNA's care plan for children with IgAN. The recommendations call for regular aerobic exercise, a healthy body weight and no smoking or vaping, and the authors also advise avoiding protein powders. The guideline's food advice centers on salt, kept to 3 to 5g a day at most, with a dietitian review at diagnosis and every 3 months.

Everyday moments are where these recommendations show up for a family, at home and at school.

• A cold or sore throat, and the urine turns red or brown: that pattern is the classic first sign, and it can come back. Ask the nephrology team how and when they want to hear about it.
• School lunches and snacks: the IPNA keeps salt to 3 to 5g a day at most, so packaged snacks and cafeteria meals are worth going over with the dietitian.
• Gym class, sports and practice: regular aerobic exercise is part of the IPNA's care plan. Ask the team whether anything should change during a flare.
• A teammate's protein shake: the IPNA advises avoiding protein powders.
• A camp or field trip form asks for vaccine records: live vaccines are the exception for a child taking daily steroids or immunosuppressive medicines.
• Missed class for labs and visits: a 504 plan or an individual health care plan, often written with the school nurse, can cover absences, make-up work and who to call.

Vaccines follow the national schedule for the child's age, the IPNA recommends. The one exception it names is live vaccines, which should not be given to children taking daily steroids or immunosuppressive medicines. That detail can matter when a school or camp asks for an updated vaccine record.

Missed class for blood draws, biopsies and specialist visits adds up over a school year. Trial Friend's school accommodations guide explains how 504 plans, IEPs and individual health care plans work for a child with a rare disease. The IPNA also recommends offering psychological and social support to the child and family from the time of diagnosis.

Moving to adult care is a step the IPNA asks teams to plan for years ahead. Transition planning can begin as early as age 11, according to the recommendations. Each young person should have a written transition plan and a named transition worker, with support for at least 6 months before and after the move to an adult clinic.

Families are not starting from scratch on any of this. Bonnie Schneider's son was diagnosed with IgAN at age 13, and she "had nowhere to turn for resources and patient support," the IgA Nephropathy Foundation's website says. She and her husband launched the foundation from their kitchen table, and the site dates its start to 2004. Schneider and Rachel McDonald of the foundation are thanked in the IPNA paper as the patient representatives who reviewed it.

The IgA Nephropathy Foundation runs a virtual support group for care partners on the third Tuesday of every month, according to its caregiver page. It meets from 7 to 8:30 in the evening, Eastern time. It also keeps IgANCare, a finder for nephrologists who treat IgAN, and a clinical trials list that shows I CAN junior as currently open. In the foundation's 2023 caregiver survey, 92% said family and friends don't understand IgAN. Families can reach the foundation's office by phone at (848) 298-4618.

What to Ask at Your Child's Next Pediatric Nephrology Visit

Trial Friend's IgA nephropathy trials page lists every open study for the condition, and Trials Near Me sorts them by distance from home. The IgA nephropathy treatment comparison sets out the approved drugs for adults, and drugmaker programs and charity funds are on the help paying page. An earlier Trial Friend post explains what each adult label does and does not promise.

IgA Nephropathy in Children, Answered for Parents and Caregivers

The first answers from these children's studies are years away, and the registry dates are estimates. EPPIK's primary completion is estimated for March 2027 and I CAN junior's for November 2028, according to ClinicalTrials.gov. The sibeprenlimab, Fabhalta and Vanrafia studies follow, with estimated dates from December 2029 to September 2031. Any pediatric label change would depend on the FDA reviewing results like these.